No definition available.
Carcinoma in situ of oropharynx, excluding all cancers
CD2_INSITU_OROPHARYNX_EXALLC
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
|
1. Apply sex-specific ruleNone |
- |
2. Check conditions
|
- |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
3 out of 7 registries used, show all original rules. |
- |
4. Check minimum number of eventsNone |
- |
5. Include endpointsNone |
- |
6. Filter based on genotype QC (FinnGen only)None |
- |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF9
- Parent code in ICD-10
- D00
Similar endpoints
↥List of similar endpoints to
Carcinoma in situ of oropharynx, excluding all cancers
based on the number of shared cases.
Similar with more cases:
- Carcinoma in situ of oral cavity and pharynx
- Neoplasms
- Any operation in hilmo
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
Case counts by codes
↥FinnGen case counts by registry codes:
No upset plot: script not run.
No upset table: script not run.
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | - | - | - |
| Only index persons | - | - | - |
| Unadjusted period prevalence (%) | |||
| Whole population | - | - | - |
| Only index persons | - | - | - |
| Median age at first event (years) | |||
| Whole population | - | - | - |
| Only index persons | - | - | - |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 53 | 18 | 35 |
| Unadjusted period prevalence (%) | 0.01 | 0.01 | 0.02 |
| Median age at first event (years) | 64.41 | 70.73 | 61.15 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
No data
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
No data available
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
unit
cases
controls
-log10(p)
N cases
N controls
(3013742) Prealbumin [Mass/volume] in Serum or Plasma
20
28
10.87
14.67
3.0
2.2
g/l
0.2
0.2
0.48
20
23
(4035726)
12
13
11.64
10.27
1.7
1.2
—
—
—
0
0
(3002256) Pathology report gross observation
13
22
7.50
7.80
1.6
1.1
—
—
—
0
0
(40768804) Tissue Pathology biopsy report
28
99
4.88
7.59
3.7
1.6
—
—
—
0
0
(46236098) ABO and Rh group [Type] in Blood by Confirmatory method
23
78
4.44
6.40
3.0
1.8
—
—
—
0
0
(3001079) Blood group antibody screen [Presence] in Serum or Plasma
34
160
4.14
5.91
5.0
3.1
—
—
—
0
0
(3044640) Blood type and Crossmatch panel - Blood
26
106
3.85
5.47
3.0
1.9
—
—
—
0
0
(40758558) Short blood count panel - Blood
21
80
3.69
4.78
10.7
5.8
—
—
—
0
0
(3000991) Gas panel - Venous blood
11
26
5.08
4.61
8.9
8.1
—
—
—
0
0
(3023368) Bacteria identified in Blood by Culture
23
103
3.18
3.96
4.9
3.9
—
—
—
0
0
(3045783) Sodium and Potassium panel [Moles/volume] - Serum or Plasma
13
43
3.68
3.53
12.5
9.7
—
—
—
0
0
(3020779) Urea [Moles/volume] in Serum or Plasma
11
33
3.94
3.41
2.5
10.8
mmol/l
9.9
9.9
0.00
11
33
(3001604) Monocytes [#/volume] in Blood
33
193
2.88
3.39
7.9
5.3
e9/l
0.6
0.6
0.51
28
162
(3006140) Bilirubin.total [Moles/volume] in Serum or Plasma
33
194
2.86
3.34
9.6
3.5
umol/l
11.2
11.3
0.02
33
178
(3006315) Basophils [#/volume] in Blood
33
194
2.86
3.34
7.9
5.3
e9/l
0.0
0.0
0.03
28
165
(3019198) Lymphocytes [#/volume] in Blood
33
195
2.83
3.29
8.0
5.4
e9/l
1.8
1.8
0.03
28
167
(586526) SARS-CoV-2 (COVID-19) RNA [Presence] in Nasopharynx by NAA with probe detection
11
34
3.82
3.27
2.0
1.3
—
—
—
0
0
(3013115) Eosinophils [#/volume] in Blood
33
199
2.74
3.11
8.0
5.3
e9/l
0.2
0.2
1.24
28
168
(1761868) Lipid panel - Serum or Plasma
6
171
0.27
3.03
3.5
3.3
—
—
—
0
0
(3044938) Influenza virus A RNA [Presence] in Specimen by NAA with probe detection
15
60
3.09
3.02
2.1
1.5
—
—
—
0
0
(46235355) HIV 1 and 2 tests - Meaningful Use set
14
54
3.16
2.99
1.2
1.7
—
—
—
0
0
(3017143) Hepatitis C virus Ab [Presence] in Serum
12
42
3.40
2.98
1.2
1.7
—
—
—
0
0
(42870588) Differential panel, method unspecified - Blood
23
119
2.65
2.89
6.4
5.7
—
—
—
0
0
(3030306) Epithelial cells.non-squamous [#/volume] in Urine by Automated count
15
62
2.98
2.85
2.1
2.8
e6/l
0.3
0.9
—
10
36
(4010399)
9
25
4.12
2.72
1.6
1.2
—
—
—
0
0
(36304419) Bacteria [Presence] in Urine
19
92
2.66
2.69
2.5
2.8
—
—
—
0
0
(3006217) Methemoglobin/Hemoglobin.total in Arterial blood
9
26
3.95
2.62
11.9
5.0
%
0.6
0.7
—
9
26
(3000494) Fungus identified in Specimen by Culture
12
46
3.08
2.56
2.2
1.7
—
—
—
0
0
(3043924) Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection
11
40
3.21
2.55
1.4
1.4
—
—
—
0
0
(3031040) Bacteria [#/volume] in Urine by Automated count
35
232
2.50
2.51
4.6
3.9
—
33.0
—
0
5
(43054903) Holo-transcobalamin II [Moles/volume] in Serum
27
161
2.38
2.43
2.2
1.9
pmol/l
95.7
94.1
0.06
13
79
(3019284) Hepatitis B virus surface Ag [Presence] in Serum
11
43
2.97
2.26
1.3
1.5
—
—
—
0
0
(3030467) Casts [#/volume] in Urine by Automated count
19
100
2.40
2.22
2.7
3.1
e6/l
0.4
0.4
0.01
14
73
(3028653) Carboxyhemoglobin/Hemoglobin.total in Arterial blood
8
27
3.30
2.03
12.6
4.9
%
1.3
1.8
—
8
27
(3038288) Influenza virus B RNA [Presence] in Specimen by NAA with probe detection
10
40
2.85
1.97
1.4
1.5
—
—
—
0
0
(3019832) Treponema pallidum Ab [Presence] in Serum
7
22
3.50
1.95
1.1
1.5
—
—
—
0
0
(3005772) Bilirubin.conjugated [Moles/volume] in Serum or Plasma
9
35
2.89
1.91
2.1
2.3
umol/l
5.3
5.5
—
9
30
(3021879) Hepatitis B virus core Ab [Presence] in Serum
8
30
2.95
1.81
1.3
1.5
—
—
—
0
0
(3009445) Proteinase 3 Ab [Units/volume] in Serum
6
18
3.62
1.80
1.0
1.1
—
—
—
0
0
(36031861) Influenza virus A and B and SARS-CoV-2 (COVID-19) and Respiratory syncytial virus RNA panel - Respiratory system specimen by NAA with probe detection
7
25
3.07
1.71
1.9
1.3
—
—
—
0
0
(40761535) Cells panel - Urine sediment
7
25
3.07
1.71
4.7
3.0
—
—
—
0
0
(3051552) Clostridioides difficile toxin genes [Presence] in Stool by NAA with probe detection
6
20
3.25
1.63
1.5
1.4
—
—
—
0
0
(40771025) 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma
24
158
1.95
1.51
2.5
2.4
nmol/l
83.9
75.5
0.59
18
139
(3022313) Gas panel - Capillary blood
5
16
3.34
1.47
3.8
4.4
—
—
—
0
0
(3042936) Bacteria identified in Isolate by Culture
13
70
2.14
1.39
2.4
1.6
—
—
—
0
0
(40762366) Oxygen capacity [Volume Fraction] in Arterial blood
5
18
2.95
1.31
14.6
8.0
—
—
—
0
0
(3003694) ABO and Rh group [Type] in Blood
16
97
1.93
1.25
1.4
1.3
—
—
—
0
0
(3029287) Urinalysis microscopic panel [#/volume] - Urine by Automated count
20
131
1.85
1.24
3.3
3.0
—
—
—
0
0
(3016293) Bicarbonate [Moles/volume] in Serum or Plasma
6
26
2.47
1.22
12.7
4.8
mmol/l
24.3
24.8
—
6
26
(3020891) Body temperature
5
20
2.65
1.18
6.0
3.4
—
—
—
0
0
(3024135) Streptococcus.beta-hemolytic [Presence] in Throat by Organism specific culture
8
41
2.12
1.14
1.3
1.3
—
—
—
0
0
(3027273) Bicarbonate [Moles/volume] in Venous blood
5
21
2.52
1.11
1.8
3.1
mmol/l
25.5
25.0
—
5
21
(3004529) Oxygen [Partial pressure] adjusted to patient's actual temperature in Venous blood
5
22
2.40
1.05
2.0
3.5
%
52.8
56.1
—
5
22
(43054914) Glucose tolerance 2 hours panel - Serum or Plasma
7
35
2.15
1.04
1.1
1.6
—
—
—
0
0
(3041096) Erythrocytes [Presence] in Urine by Automated
5
100
0.45
1.03
2.6
3.4
—
—
—
0
0
(3036481) Cortisol [Moles/volume] in Serum or Plasma
7
36
2.08
1.01
2.7
1.9
nmol/l
369.6
396.1
—
7
31
(3010517) Carboxyhemoglobin/Hemoglobin.total in Venous blood
6
27
2.37
0.97
2.0
2.5
%
2.2
1.4
—
6
27
(3018095) Leukocytes [#/volume] in Urine
19
131
1.70
0.96
3.2
3.6
e6/l
8.0
65.7
1.06
12
92
(3021589) Normoblasts [#/volume] in Blood
24
177
1.65
0.95
10.0
8.6
e9/l
0.0
0.0
0.50
18
143
(3007853) Bacteria identified in Skin by Aerobe culture
8
45
1.91
0.89
2.4
2.1
—
—
—
0
0
(3019225) pH of Specimen
6
31
2.05
0.87
13.8
3.3
—
—
—
0
0
(3011397) Hemoglobin [Presence] in Urine by Test strip
14
92
1.71
0.83
5.3
3.2
—
—
—
0
0
(3004119) Hemoglobin [Mass/volume] in Venous blood
6
33
1.92
0.82
2.2
3.2
g/l
130.5
129.9
—
6
33
(3002032) Base excess in Venous blood by calculation
7
39
1.91
0.76
2.3
4.7
mmol/l
1.0
1.7
—
7
33
(3021447) Carbon dioxide [Partial pressure] in Venous blood
7
39
1.91
0.76
2.3
4.8
kpa
5.7
5.7
—
7
39
(3020460) C reactive protein [Mass/volume] in Serum or Plasma
45
405
1.73
0.76
30.0
12.4
mg/l
37.9
21.8
2.01
39
312
(3024950) Chlamydia trachomatis DNA [Presence] in Urine by NAA with probe detection
5
27
1.94
0.70
1.2
1.7
—
—
—
0
0
(3013707) Erythrocyte sedimentation rate by Westergren method
35
297
1.53
0.68
6.3
4.1
mm/h
15.9
12.1
0.78
35
272
(3012544) pH of Venous blood
7
44
1.68
0.68
2.3
4.8
—
—
—
0
0
(3019800) Troponin T.cardiac [Mass/volume] in Serum or Plasma
23
180
1.49
0.66
4.0
3.8
ng/l
15.8
53.3
1.55
17
137
(3019060) Gas panel - Arterial blood
5
29
1.80
0.65
9.2
4.3
—
—
—
0
0
(3024354) Oxygen [Partial pressure] in Venous blood
6
34
1.86
0.61
2.2
3.0
kpa
4.0
4.7
—
6
34
(3022145) Colonoscopy Study observation
6
37
1.70
0.58
1.5
1.2
—
—
—
0
0
(706163) SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection
28
236
1.40
0.51
2.9
2.7
—
—
—
0
0
(3037467) Urinalysis macro (dipstick) panel - Urine
30
259
1.36
0.45
4.3
4.4
—
—
—
0
0
(3013721) Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
17
135
1.38
0.42
3.9
2.7
u/l
37.4
29.4
0.44
17
123
(4094501)
0
15
0.00
0.42
0.0
1.0
—
—
—
0
0
(3026008) Bacteria identified in Urine by Culture
14
109
1.39
0.38
2.9
2.8
—
—
—
0
0
(3044889) 12 lead EKG panel
33
294
1.32
0.38
5.5
3.6
—
—
—
0
0
(3026910) Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
30
269
1.27
0.30
4.8
2.9
u/l
68.0
50.6
0.47
30
256
(40761511) CBC panel - Blood by Automated count
46
439
1.36
0.25
22.6
11.5
—
—
—
0
0
(3017895) Helicobacter pylori Ab [Units/volume] in Serum
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
(3029338) Protein.monoclonal band 3 [Mass/volume] in Serum or Plasma by Electrophoresis
0
11
0.00
0.21
0.0
1.0
—
0.0
—
0
11
(3029379) Protein.monoclonal band 4 [Mass/volume] in Serum or Plasma by Electrophoresis
0
11
0.00
0.21
0.0
1.0
—
0.0
—
0
11
(3000570) Elastase.pancreatic [Mass/mass] in Stool
0
11
0.00
0.21
0.0
1.5
—
295.1
—
0
5
(3012110) Lysozyme [Mass/volume] in Serum or Plasma
0
12
0.00
0.21
0.0
2.3
—
12.3
—
0
12
(3010156) C reactive protein [Mass/volume] in Serum or Plasma by High sensitivity method
0
13
0.00
0.21
0.0
1.5
—
2.2
—
0
8
(3035797) Protein.monoclonal band 2 [Mass/volume] in Serum or Plasma by Electrophoresis
0
14
0.00
0.20
0.0
1.0
—
0.0
—
0
14
(3001784) Prostate Specific Ag Free/Prostate specific Ag.total in Serum or Plasma
15
172
0.82
0.19
3.0
2.8
%
13.6
24.5
—
5
67
(3009542) Hematocrit [Volume Fraction] of Blood
40
379
1.23
0.19
29.2
13.1
%
36.7
41.2
1.16
26
260
(3041942) Cyclic citrullinated peptide Ab [Units/volume] in Serum
5
66
0.73
0.18
1.4
1.3
—
22.3
—
0
25
(3013512) EKG study
11
128
0.82
0.15
5.5
4.2
—
—
—
0
0
(40760892) CBC W Ordered Manual Differential panel - Blood
10
84
1.23
0.15
7.3
3.8
—
—
—
0
0
(40763086) Leukocyte esterase [Presence] in Urine by Automated test strip
13
141
0.90
0.06
5.0
3.6
—
—
—
0
0
(3015736) pH of Urine
16
149
1.11
0.06
4.8
3.3
—
—
—
0
0
(3002385) Erythrocyte distribution width [Ratio]
33
341
0.91
0.06
33.0
15.2
%
14.2
13.6
1.54
33
331
(40764999) Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)
39
381
1.09
0.04
22.1
11.7
ml/min/173m2
80.3
77.9
0.29
34
312
(3020564) Creatinine [Moles/volume] in Serum or Plasma
43
438
0.90
0.03
34.0
14.4
umol/l
76.9
83.9
1.00
43
438
(3027944) Amphetamines [Presence] in Urine
0
8
0.00
0.00
0.0
1.6
—
—
—
0
0
(3001019) Free T4 and TSH panel - Serum or Plasma
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
(3006093) Chlamydia trachomatis DNA [Presence] in Specimen by NAA with probe detection
0
9
0.00
0.00
0.0
2.2
—
—
—
0
0
(3029080) Hemoglobin [Entitic mass] in Reticulocytes
0
5
0.00
0.00
0.0
1.8
—
31.8
—
0
5
(3011288) Drugs identified in Urine by Screen method
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
(3007368) IgG [Mass/volume] in Cerebral spinal fluid
0
6
0.00
0.00
0.0
1.2
—
54.5
—
0
6
(36033641) SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Rapid immunoassay
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
(40768797) Stomach Pathology biopsy report
5
58
0.85
0.00
1.0
1.1
—
—
—
0
0
(3024474) Albumin [Mass/volume] in Cerebral spinal fluid
0
6
0.00
0.00
0.0
1.2
—
295.2
—
0
6
(3011166) Borrelia burgdorferi Ab [Presence] in Cerebral spinal fluid
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
(40759883) Oligoclonal Bands IgG [Presence] in Cerebral spinal fluid by Isoelectric focusing
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
(3049717) Cytology report of Urine Cyto stain
0
7
0.00
0.00
0.0
2.0
—
—
—
0
0
(3028300) Cannabinoids [Presence] in Urine
0
9
0.00
0.00
0.0
1.7
—
—
—
0
0
(3027008) Opiates [Presence] in Urine
0
9
0.00
0.00
0.0
1.7
—
—
—
0
0
(3017569) Oxygen content in Arterial blood
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
(3011371) Neisseria gonorrhoeae DNA [Presence] in Specimen by NAA with probe detection
0
9
0.00
0.00
0.0
2.1
—
—
—
0
0
(3016879) Cocaine [Presence] in Urine
0
9
0.00
0.00
0.0
1.7
—
—
—
0
0
(21494815) CD4 cells/100 lymphocytes in Specimen
0
5
0.00
0.00
0.0
2.2
—
—
—
0
0
(3009595) Pneumocystis jiroveci DNA [Presence] in Specimen by NAA with probe detection
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
(1001926) Buprenorphine [Presence] in Urine by Screen method
0
7
0.00
0.00
0.0
1.6
—
—
—
0
0
(3044242) Glucose [Moles/volume] in Arterial blood
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
(4027681)
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
(3000764) Benzodiazepines [Presence] in Urine
0
9
0.00
0.00
0.0
1.7
—
—
—
0
0
(21494670) JAK2 gene exon 14 targeted mutation analysis in Blood or Tissue by Molecular genetics method
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
(3021125) Hepatitis C virus RNA [Presence] in Serum or Plasma by NAA with probe detection
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
(3045424) Erythrocytes [Presence] in Urine
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
(3021901) Oxygen saturation in Capillary blood
0
7
0.00
0.00
0.0
2.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint CD2_INSITU_OROPHARYNX_EXALLC and mortality.
Females
No dataMales
No dataMortality risk
Mortality risk for people of age
years, who have CD2_INSITU_OROPHARYNX_EXALLC.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | No data |
| 5 | No data | No data |
| 10 | No data | No data |
| 15 | No data | No data |
| 20 | No data | No data |
Relationships between endpoints
↥Index endpoint: CD2_INSITU_OROPHARYNX_EXALLC – Carcinoma in situ of oropharynx, excluding all cancers
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
Extremity
rg [CI]
Extremity
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data